Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Tom Nolan reviews this week’s research Is it time to treat male partners of women with bacterial vaginosis? A trial in the New England Journal of Medicine recruited women with confirmed bacterial ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin ...

The use of GLP-1 receptor agonists, like semaglutide, to treat type 2 diabetes is not associated with an increased risk of ...

An orange a day, regular moderate-to-vigorous exercise, and GLP-1 drugs for diabetes treatment have all been linked to a ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes compared with dipeptidyl peptidase 4 inhibitors, results of a target trial ...

MONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) ...

Owing to the increasing popularity of GLP-1 receptor agonists and the inconsistency of observational studies on this potential association, we did a large, observational study to estimate the average ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.